Biopharma
ByCan Vanda Pharma’s FDA Approval of Nereus Unlock a New Growth Chapter in Motion-Sickness Treatment?
New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the…
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed Momentum for Stenoparib in Hard-to-Treat Cancers?
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
Do Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access and Market Expansion?
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights how multiple reimbursement…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning Point for Vanda Pharmaceuticals?
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the U.S. Food and…
Does the U.S. Exit from WHO Redefine Global Health Governance? Washington Completes Historic Withdrawal
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
Is Partnership-Led Innovation Replacing M&A in Oncology? BMS and Janux Strike $850 Million T-Cell Engager Deal
January 2026 Executive Summary Bristol Myers Squibb (BMS) has entered into a strategic collaboration with Janux Therapeutics, a…
